As the world's biggest health care products company, Johnson & Johnson has massive scope: a sampling of its products includes Benadryl, Band-Aids, Neutrogena, Tylenol, Motrin, and Listerine. How do you boost something that's already big? Acquisitions and revenue growth (notably in beauty products). While domestic sales rose 6%, international sales decreased about 1% thanks to divestitures, currency issues, and upheaval in Venezuela. Even if the international climate gets more comfortable, the company long known for its pioneering innovation could face competition from generics that could eat into sales.
Company Info
| CEO | Alex Gorsky |
| CEO Title | Chairman & Chief Executive Officer |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | New Brunswick, NJ |
| Website | www.jnj.com |
| Years on Fortune 500 List | 23 |
| Employees | 126,400 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $71,890 |
| Profits ($M) | $16,540 |
| Assets ($M) | $141,208 |
| Total Stockholder Equity ($M) | $70,418 |
| Market Value — as of March 31, 2017 ($M) | $337,642 |
Profit Ratios
| Profit as % of Revenues | 23% |
| Profits as % of Assets | 11.7% |
| Profits as % of Stockholder Equity | 23.5% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 593 |
| EPS % Change (from 2015) | 8.2% |
| EPS % Change (5 year annual rate) | 11.2% |
| EPS % Change (10 year annual rate) | 4.7% |
Total Return
| Total Return to Investors (2016) | 15.3% |
| Total Return to Investors (5 year, annualized) | 15.3% |
| Total Return to Investors (10 year, annualized) | 9% |
